Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib

被引:1
|
作者
Moser, Monika [1 ,2 ]
Radu, Iuliana-Pompilia [1 ,2 ]
Dufour, Jean-Francois [1 ,2 ]
机构
[1] Univ Bern, Hepatol, Dept Clin Res, Bern, Switzerland
[2] Inselspital Bern, Univ Clin Visceral Surg & Med, Bern, Switzerland
来源
JGH OPEN | 2021年 / 5卷 / 08期
关键词
liver cancer; oncology; quality of life; sorafenib; treatment; QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; PROGNOSTIC-FACTOR; SURVIVAL; THERAPY; PREDICTORS; DISEASE;
D O I
10.1002/jgh3.12533
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: Treatment with sorafenib causes diverse side effects, which limits adherence. This work assesses whether Home Care, a psychosocial nursing intervention, prolongs the duration of treatment in patients with advanced hepatocellular carcinoma (HCC) and if it influences health-related quality of life (HRQL). Methods and Results: This is a cohort study using data from patients receiving sorafenib in the prospective Bern HCC Cohort at the University Hospital. Duration of treatment, overall survival, and HRQL using the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire were compared in the two groups. A total of 173 patients were eligible for the analysis. Among them, 141 were in the Home Care program, and 32 were not. Patients with Home Care had a significantly longer duration of treatment (265 days vs 152 days, P = 0.003) and a better functional well-being (17.7 vs 12.5, P = 0.015). Conclusion: Psychosocial interventions such as Home Care are a valid method in improving adherence to sorafenib and can therefore be recommended.
引用
收藏
页码:864 / 870
页数:7
相关论文
共 50 条
  • [1] Hepatocellular carcinoma treated with sorafenib
    Han, G.
    Zhao, Y.
    Qi, X.
    Fan, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) : 1347 - 1348
  • [2] Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Pomej, Katharina
    Scheiner, Bernhard
    Park, Dabin
    Bauer, David
    Balcar, Lorenz
    Meischl, Tobias
    Mandorfer, Mattias
    Reiberger, Thomas
    Muller, Christian
    Trauner, Michael
    Pinter, Matthias
    CANCERS, 2020, 12 (10) : 1 - 14
  • [3] Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib
    Cabibbo, Giuseppe
    Rolle, Emanuela
    De Giorgio, Massimo
    Genco, Chiara
    Pressiani, Tiziana
    Spada, Francesca
    Sacco, Rodolfo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (12) : 1807 - 1816
  • [4] Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
    Di Costanzo, Giovan Giuseppe
    de Stefano, Giorgio
    Tortora, Raffaella
    Farella, Nunzia
    Addario, Luigi
    Lampasi, Filippo
    Lanza, Alfonso Galeota
    Cordone, Gabriella
    Imparato, Michele
    Caporaso, Nicola
    FUTURE ONCOLOGY, 2015, 11 (06) : 943 - 951
  • [5] Biological downstaging of intermediate hepatocellular carcinoma in patients treated with sorafenib
    Vitale, A.
    Morales, R. Ramirez
    Cillo, U.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S89 - S89
  • [6] Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
    Pinter, M.
    Sieghart, W.
    Hucke, F.
    Graziadei, I.
    Vogel, W.
    Maieron, A.
    Koenigsberg, R.
    Weissmann, A.
    Kornek, G.
    Matejka, J.
    Stauber, R.
    Buder, R.
    Gruenberger, B.
    Schoeniger-Hekele, M.
    Mueller, C.
    Peck-Radosavljevic, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 949 - 959
  • [7] BIOLOGICAL DOWNSTAGING OF INTERMEDIATE HEPATOCELLULAR CARCINOMA IN PATIENTS TREATED WITH SORAFENIB
    Vitale, Alessandro
    Morales, Rafael Ramirez
    Cillo, Umberto
    HEPATOLOGY, 2010, 52 (04) : 883A - 884A
  • [8] Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib
    da Costa Ferreira, Caroline Petersen
    Ribeiro, Mauricio Alves
    Szutan, Luiz Arnaldo
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (03): : 275 - 283
  • [9] Biomarkers of Apoptosis and Necrosis in Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Godin, Corinne
    Louandre, Christophe
    Bodeau, Sandra
    Diouf, Momar
    Saidak, Zuzana
    Conte, Marie-Alix
    Chauffert, Bruno
    Barbare, Jean-Claude
    Barget, Nathalie
    Trinchet, Jean-Claude
    Ganne, Nathalie
    Galmiche, Antoine
    ANTICANCER RESEARCH, 2015, 35 (03) : 1803 - 1808
  • [10] Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
    Apostolidis, Leonidas
    Pfeiffenberger, Jan
    Gotthardt, Daniel
    Radeleff, Boris
    Mehrabi, Arianeb
    Schemmer, Peter
    Jaeger, Dirk
    Schirmacher, Peter
    Stremmel, Wolfgang
    Schulze-Bergkamen, Henning
    Springfeld, Christoph
    Weiss, Karl Heinz
    GASTROINTESTINAL TUMORS, 2018, 5 (1-2) : 38 - 46